Cel-Sci (CVM) FDA Approvals $1.28 +0.09 (+7.56%) Closing price 11/13/2026 04:10 PM EasternExtended Trading$1.27 -0.01 (-0.78%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisChartEarningsFDA EventsInsider TradesNews and TrendsOwnershipSEC Filings Cel-Sci's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Cel-Sci (CVM). Over the past two years, Cel-Sci has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Multikine. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Multikine FDA Regulatory Events Multikine is a drug developed by Cel-Sci for the following indication: Head and Neck Cancer. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Provided Update - October 26,2026Provided Update Drug: MultikineAnnounced Date: October 26, 2026Indication: Head and Neck CancerAnnouncementCEL-SCI Corporation announced positive new pre-surgical tumor response and safety analyses from its completed Phase 3 study of Multikine® (Leukocyte Interleukin, Injection)*.Read Announcement Cel-Sci FDA Events - Frequently Asked Questions Has Cel-Sci received FDA approval? As of now, Cel-Sci (CVM) has not received any FDA approvals for its therapy in the last two years. What drugs has Cel-Sci submitted to the FDA? In the past two years, Cel-Sci (CVM) has reported FDA regulatory activity for Multikine. What is the most recent FDA event for Cel-Sci? The most recent FDA-related event for Cel-Sci occurred on October 26, 2026, involving Multikine. The update was categorized as "Provided Update," with the company reporting: "CEL-SCI Corporation announced positive new pre-surgical tumor response and safety analyses from its completed Phase 3 study of Multikine® (Leukocyte Interleukin, Injection)*." What conditions do Cel-Sci's current drugs treat? Currently, Cel-Sci has one therapy (Multikine) targeting the following condition: Head and Neck Cancer. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events BioCryst Pharmaceuticals FDA EventsRezolute FDA EventsWAVE Life Sciences FDA EventsZai Lab FDA EventsMerck & Co., Inc. FDA EventsAltimmune FDA EventsPlus Therapeutics FDA EventsAlpha Tau Medical FDA EventsImmuneering FDA EventsMetaVia FDA EventsNeonc Technologies FDA EventsTraws Pharma FDA EventsTakeda Pharmaceutical FDA EventsBridgeBio Pharma FDA EventsCoherus Oncology FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Oncocyte FDA Events Tonix Pharmaceuticals FDA Events Tiziana Life Sciences FDA Events Atara Biotherapeutics FDA Events Tenaya Therapeutics FDA Events PDS Biotechnology FDA Events Rani Therapeutics FDA Events PMV Pharmaceuticals FDA Events Corbus Pharmaceuticals FDA Events Cardiff Oncology FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NYSEAMERICAN:CVM last updated on 10/26/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cel-Sci Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Cel-Sci With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Provided Update - October 26,2026Provided Update Drug: MultikineAnnounced Date: October 26, 2026Indication: Head and Neck CancerAnnouncementCEL-SCI Corporation announced positive new pre-surgical tumor response and safety analyses from its completed Phase 3 study of Multikine® (Leukocyte Interleukin, Injection)*.Read Announcement